OMass Therapeutics, a UK BioTech company developing small molecule therapeutics against highly validated target ecosystems, announced an oversubscribed €275 million (£230 million) Series C round. The round was co-led by…
Therapeutics
-
-
Investment
Biotech Stock Alaunos Therapeutics (NASDAQ: TCRT) Sees Triple Digit Gains on Acquisition and Funding
Alaunos completes its acquisition of Velaris Therapeutics alongside an oversubscribed $350 million private placement, adding a pulmonary arterial hypertension pipeline led by VLR199. Investorideas.com (www.investorideas.com) a trusted platform for investing…
-
Investment
Tvardi Therapeutics (Nasdaq: TVRD) Soars on Positive Phase 1 Results for Next-Gen STAT3 Inhibitor TTI-109
Tvardi’s next-generation STAT3 inhibitor TTI-109 confirmed rapid prodrug conversion, dose-proportional exposure, and improved tolerability versus TTI-101 in Phase 1 testing. Investorideas.com (www.investorideas.com) a trusted platform for investing ideas, including biotech…
-
BriaCell Therapeutics (BCTX) priced a public offering of 5.37M units, with each unit consisting of one common share and one warrant. Each unit is being sold to the public at…
-
Investor Insight Cardiol Therapeutics is positioned with a late-stage lead asset, multiple orphan indications, strong clinical proof-of-concept data, and a differentiated non-immunosuppressive approach to inflammatory heart disease. The company’s 2025–2026…
